CD23+ mantle cell lymphoma: A clinical pathologic entity associated with superior outcome compared with CD23- disease

American Journal of Clinical Pathology

Volumn 130, Issue 2, 2008, Pages 166-177

  Kelemen, Katalin ^a   Peterson, LoAnn C ^a   Helenowski, Irene ^a   Goolsby, Charles L ^a   Jovanovic, Borko ^a   Miyata, Sarah ^a   Aranha, Olivia ^a   Rosen, Steven T ^a   Winter, Jane N ^a   Nelson, Beverly P ^a   Gordon, Leo I ^a   Evens, Andrew M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NW Univ Feinberg School of Medicine   (United States)

Author keywords

CD23; Disease outcome; Flow cytometric immunophenotyping; Mantle cell lymphoma; Prognosis

Indexed keywords

CD23 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LYMPHATIC METASTASIS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, IGE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 48649106006     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/R94MAFJY5EA4A8C3     Document Type: Article

References (41)

1. Swerdlow S, Berger F, Issacson PI, et al. Mantle cell lymphoma. In: Jaffe E, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2001:168-170. World Health Organization Classification of Tumours.
2. Van Den Berghe H, Parloir C, David G, et al. A new characteristic karyotypic anomaly in lymphoproliferative disorders. Cancer. 1979;44:188-195.
3. Medeiros LJ, Van Krieken JH, Jaffe ES, et al. Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood. 1990;76:2086-2090.
4. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-3732.
5. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984-1992.
6. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36:115-127.
7. Gong JZ, Lagoo AS, Peters D, et al. Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol. 2001;116:893-897.
8. Schlette E, Fu K, Medeiros LJ. CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases. Am J Clin Pathol. 2003;120:760-766.
9. DiRaimondo F, Albitar M, Huh Y, et al. The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer. 2002;94:1721-1730.
10. Dewald GW, Brockman SR, Paternoster SF, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003;121:287-295.
11. Monaghan SA, Peterson LC, James C, et al. Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL). Cytometry B Clin Cytom. 2003;56:30-42.
12. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
13. Montserrat E, Bosch F, Lopez-Guillermo A, et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol. 1996;14:941-944.
14. Valdez R, Kroft SH, Ross CW, et al. Cerebrospinal fluid involvement in mantle cell lymphoma. Mod Pathol. 2002;15:1073-1079.
15. Evens AM, Winter JN, Hou N, et al. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long term followup in newly diagnosed mantle cell lymphoma. Br J Haematol. 2008;140:385-393.
16. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1958;22:719-723.
18. Cox DR. Regression models and life tables. J Royal Stat Soc (B). 1972;34:187-220.
19. H genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101:4975-4981.
20. Rubio-Moscardo F, Climent J, Siebert R, et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood. 2005;105:4445-4454.
21. Kumar S, Green GA, Teruya-Feldstein J, et al. Use of CD23 (BU38) on paraffin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma. Mod Pathol. 1996;9:925-929.
22. Koiso H, Tsukamoto N, Miyawaki S, et al. Quantitative analysis of cyclin D1 and CD23 expression in mantle cell lymphoma and B-chronic lymphocytic leukemia. Leuk Res. 2002;26:809-815.
23. Tworek JA, Singleton TP, Schnitzer B, et al. Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma. Am J Clin Pathol. 1998;110:582-589.
24. Kilo MN, Dorfman DM. The utility of flow cytometric immunophenotypic analysis in the distinction of small lymphocytic lymphoma/chronic lymphocytic leukemia from mantle cell lymphoma. Am J Clin Pathol. 1996;105:451-457.
25. Matutes E, Parry-Jones N, Brito-Babapulle V, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma. 2004;45:2007-2015.
26. Xu Y, McKenna RW, Asplund SL, et al. Comparison of immunophenotypes of small B-cell neoplasms in primary lymph node and concurrent blood or marrow samples. Am J Clin Pathol. 2002;118:758-764.
27. Cuneo A, Balboni M, Piva N, et al. Atypical chronic lymphocytic leukaemia with t(11;14)(q13;q32): karyotype evolution and prolymphocytic transformation. Br J Haematol. 1995;90:409-416.
28. Gervasi F, Lo Verso R, Giambanco C, et al. Flow cytometric immunophenotyping analysis of patterns of antigen expression in non-Hodgkin's B cell lymphoma in samples obtained from different anatomic sites. Ann N Y Acad Sci. 2004;1028:457-462.
29. Echeverri C, Fisher S, King D, et al. Immunophenotypic variability of B-cell non-Hodgkin lymphoma: a retrospective study of cases analyzed by flow cytometry. Am J Clin Pathol. 2002;117:615-620.
30. Wong KF, Chan JK, So JC, et al. Mantle cell lymphoma in leukemic phase: characterization of its broad cytologic spectrum with emphasis on the importance of distinction from other chronic lymphoproliferative disorders. Cancer. 1999;86:850-857.
31. Molina TJ, Delmer A, Cymbalista F, et al. Mantle cell lymphoma, in leukaemic phase with prominent splenomegaly: a report of eight cases with similar clinical presentation and aggressive outcome. Virchows Arch. 2000;437:591-598.
32. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558-565.
33. Sarfati M. CD23 and chronic lymphocytic leukemia. Blood Cells. 1993;19:591-599.
34. Dadmarz R, Cawley JC. Heterogeneity of CLL: high CD23 antigen and alpha IFN receptor expression are features of favourable disease and of cell activation. Br J Haematol. 1988;68:279-282.
35. Geisler CH, Larsen JK, Hansen NE, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood. 1991;78:1795-1802.
36. Sarfati M, Bron D, Lagneaux L, et al. Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood. 1988;71:94-98.
37. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185-197.
38. Kienle D, Katzenberger T, Ott G, et al. Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. J Clin Oncol. 2007;25:1-13.
39. Wiestner A, Tehrani M, Chiorazzi M, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood. 2007;109:4599-4606.
40. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23:7013-7023.
41. Raty R, Franssila K, Joensuu H, et al. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol. 2002;69:11-20.